Clinical Trial Protocol
Iranian Registry of Clinical Trials

30 May 2026

Evaluation of Tissue Plasminogen Activator (tPA) in comparition of anticoagulation for treatment of critical COVID 19 patient

Protocol summary

Study aim
Evaluation of thrombolytic and anticoagulant in treatment of COVID-19 patients

Design
This study is a randomized control trial with tree arm parallel group without double blind. We have three group, thrombolytic, UFH, and control. Randomization performed with Randlist software

Settings and conduct
This is a RCT of Tabriz, university of medical sciences. .The patients will be divided to three group. Two cases and control group. First will be started on tPA 25 mg over 2 hours and 22 mg next 22 hours. Second group on therapeutic dose of anticoagulation (UFH with traumatic dose) and third group will be control with usual medications.

Participants/Inclusion and exclusion criteria
Critical COVID patients with d.Dimer more than 3000 ng/ml

Intervention groups
The patients will started on thrombolytic (tPA) or UFH and third group will be as a control .

Main outcome variables
Some main outcome of this study are improve of oxygenasion, SOFA score and decrease of mortality

General information

Reason for update

Acronym
TACOVID

IRCT registration information
IRCT registration number: **IRCT20200515047456N1**
Registration date: **2020-06-28, 1399/04/08**
Registration timing: **registered_while_recruiting**

Last update: **2020-06-28, 1399/04/08**
Update count: **0**

Registration date
2020-06-28, 1399/04/08

Registrant information

Name
Farid Rashidi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 41 3336 4901
Email address
fr2652@yahoo.com

Recruitment status
Recruitment complete

Funding source

Expected recruitment start date
2020-06-17, 1399/03/28

Expected recruitment end date
2020-07-15, 1399/04/25

Actual recruitment start date
empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
Evaluation of Tissue Plasminogen Activator (tPA) in comparition of anticoagulation for treatment of critical COVID 19 patient

Public title
The role of anticoagulant and thrombolitic in treatment of COVID patients

Purpose
Treatment

Inclusion/Exclusion criteria

Inclusion criteria:
COVID patients with P/F ratio less than 100 D.dimer more

than 3000 without response to other medications

Exclusion criteria:

Active bleeding Platelet less than 30000 Without any contraindication for thrombolytic therapy

Age

From **15 years** old to **70 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant

Sample size

Target sample size: **15**

Randomization (investigator's opinion)

Randomized

Randomization description

Randomization by block method and Randlist software according to Seed schedule with 420059136 number

Blinding (investigator's opinion)

Single blinded

Blinding description

Only participants in this study were blinded, given that the patients are unconscious and under mechanical ventilation

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Tabriz University of Medical Sciences

Street address

Farid Rashidi, MD, Tuberculosis and Lung diseases research center, Imam Reza Hospital, Daneshgah St, Tabriz

City

Tabriz

Province

East Azarbaijan

Postal code

5166614756

Approval date

2020-05-18, 1399/02/29

Ethics committee reference number

IR.TBZMED.REC.1399.127

Health conditions studied

1

Description of health condition studied

COVID 19

ICD-10 code

U07.1

ICD-10 code description

COVID-19, virus identified

Primary outcomes

1

Description

Improve of oxygenasion

Timepoint

From first to 6th days of study

Method of measurement

Arterial blood gas

2

Description

Improve SOFA score

Timepoint

From first to 6th days of study

Method of measurement

Questionnaire

3

Description

Improve compliance

Timepoint

From first to 6th days of study

Method of measurement

Ventilator parameter

4

Description

decrease d.Dimer level

Timepoint

From first to 6th days of study

Method of measurement

Blood sample

Secondary outcomes

empty

Intervention groups

1

Description

Control group: Without placebo

Category

Treatment - Drugs

2

Description
Intervention group: first intervention group, anticoagulant. ، the patients will be started on unfractional heparin. Blood sample will tale to keep PTT more than 50

Category
Treatment - Drugs

3

Description
Intervention group: second intervention group, thrombolytic (tPA). The will be started 25 mg over 2 hours and 25 mg for next 22 hours

Category
Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center
Imam Reza Hostital

Full name of responsible person
Farid Rashidi, MD

Street address
Danrshgah

City
Tabriz

Province
Ardabil

Postal code
5166614756

Phone
+98 41 3336 4901

Email
fr2652@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Tabriz University of Medical Sciences

Full name of responsible person
Farid Rashidi

Street address
Daneshgah

City
Tabriz

Province
East Azarbaijan

Postal code
5166614756

Phone
+98 41 3336 4901

Email
fr2652@yahoo.com

Grant name
Dr. Mohammad Samiea

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?
Yes

Title of funding source
Tabriz University of Medical Sciences

Proportion provided by this source
10

Public or private sector
Public

Domestic or foreign origin
Domestic

Category of foreign source of funding
empty

Country of origin

Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Tabriz University of Medical Sciences

Full name of responsible person
Farid Rashidi

Position
Assistance professor of medicine

Latest degree
Subspecialist

Other areas of specialty/work
Internal Medicine

Street address
Daneshgah

City
تبریز

Province
East Azarbaijan

Postal code
5166614756

Phone
+98 41 3336 4901

Email
fr2652@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Tabriz University of Medical Sciences

Full name of responsible person
Farid Rashidi

Position
Assistance professor of medicine

Latest degree
Subspecialist

Other areas of specialty/work
Internal Medicine

Street address
Daneshgah

City
Tabriz
Province
East Azarbaijan
Postal code
5166614756
Phone
+98 41 3336 0901
Email
fr2652@yahoo.com

Person responsible for updating data

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Farid Rshidi
Position
Assistance professor of medicine
Latest degree
Subspecialist
Other areas of specialty/work
Internal Medicine
Street address
Daeshgah
City
Tabriz
Province
East Azarbaijan
Postal code
5166614756
Phone
0413364901
Email
fr2652@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
Demographic information
When the data will become available and for how long
Six month after publication
To whom data/document is available
Researchers who work in university
Under which criteria data/document could be used
Only for information
From where data/document is obtainable
Via e.mail
What processes are involved for a request to access data/document
Send a request via e.mail
Comments